| Literature DB >> 32486960 |
Nasim Shahidi Hamedani1, Jens Müller1, Fabian Tolle2, Heiko Rühl1, Behnaz Pezeshkpoor1, Kerstin Liphardt1, Johannes Oldenburg1, Günter Mayer2, Bernd Pötzsch1.
Abstract
Activated protein C (APC) is a serine protease with anticoagulant and cytoprotective activities. Nonanticoagulant APC mutants show beneficial effects as cytoprotective agents. To study, if such biased APC signaling can be achieved by APC-binding ligands, the aptamer technology has been used. A G-quadruplex-containing aptamer, G-NB3, has been selected that binds to the basic exosite of APC with a KD of 0.2 nM and shows no binding to APC-related serine proteases or the zymogen protein C. G-NB3 inhibits the inactivation of activated cofactors V and VIII with IC50 values of 11.6 and 13.1 nM, respectively, without inhibiting the cytoprotective and anti-inflammatory functions of APC as tested using a staurosporine-induced apoptosis assay and a vascular barrier protection assay. In addition, G-NB3 prolongs the plasma half-life of APC through inhibition of APC-serine protease inhibitor complex formation. These physicochemical and functional characteristics qualify G-NB3 as a promising therapeutic agent usable to enhance the cytoprotective functions of APC without increasing the risk of APC-related hemorrhage.Entities:
Keywords: activated protein C; aptamer; cytoprotection; exosite; trauma-induced coagulopathy
Year: 2020 PMID: 32486960 DOI: 10.1089/nat.2020.0844
Source DB: PubMed Journal: Nucleic Acid Ther ISSN: 2159-3337 Impact factor: 5.486